Navigation Links
Prostate cancer study proves drug delays disease progression
Date:1/23/2012

(TORONTO, Canada Jan. 24, 2012) For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).

The findings are published online today in The Lancet. "The results prove that using active surveillance plus dutasteride is a viable, safe and effective treatment option for men who often undergo aggressive local treatment despite low risk of dying from the disease," says Dr. Fleshner, a surgical oncologist in UHN's Princess Margaret Cancer Program and Professor of Surgery at the University of Toronto. Dr. Fleshner also holds the Love Chair in Prostate Cancer Prevention Research.

"This is very good news for men with low-risk disease because aggressive treatment can have a major impact on their quality of life, with risks of impotence and incontinence," says Dr. Fleshner.

The three-year clinical trial enrolled 302 men between the ages of 48 and 82 diagnosed with low-risk localized prostate cancer and regularly monitored for clinical changes a treatment option called "active surveillance". In the trial known as REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management of prostate cancer) participants were randomized 1:1 to receive dutasteride or a matching placebo daily. The men also underwent biopsies at 1.5 and three years.

The study showed a significant delay in disease progression in the men treated with dutasteride 36% compared with 23% who received the placebo. As well, the final biopsies showed the men treated with the drug were less likely to have cancer detected 36% compared with 31%.

"This is the first study to show that a 5a-reductase inhibitor such as dutasteride reduces the need for aggressive treatment in low-risk disease," says Dr. Fleshner. "The drug, currently commonly used to treat enlarged prostate, works by inhibiting the male sex hormone that causes the enlargement in the first place."

Dr. Fleshner says a small percentage of men reported drug-related side effects including sexual difficulty with either desire or erections (5%), or breast tenderness or enlargement (3%). "It's important to realize that these drugs have been around for almost 20 years in clinical practice to treat enlarged prostates and so we have a wealth of knowledge about their side effects, which are reversible if the drug is stopped."

Participants were also assessed for cancer-related anxiety and the men on dutasteride reported feeling much less anxious because their biopsies and PSA values improved, adds Dr. Fleshner. (PSA or prostate-specific antigen is a blood test used to help diagnose prostate cancer.)

The Canadian Cancer Society estimates 25,500 new cases of prostate cancer will be diagnosed this year and that 4,100 men will die from the disease.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer
2. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
3. Music May Ease Anxiety, Pain in Prostate Biopsy Patients
4. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
5. Scientists Identify Inherited Prostate Cancer Gene
6. Headphone music eases anxiety during prostate biopsies
7. PSA Test for Prostate Cancer Doesnt Save Lives: Study
8. Mass prostate cancer screening doesnt reduce deaths
9. Proton therapy effective prostate cancer treatment
10. PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies
11. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: